Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients - PubMed (original) (raw)
Clinical Trial
. 2000 Nov-Dec;7(6):1299-304.
doi: 10.3892/or.7.6.1299.
Affiliations
- PMID: 11032933
- DOI: 10.3892/or.7.6.1299
Clinical Trial
Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients
Y Murata et al. Oncol Rep. 2000 Nov-Dec.
Abstract
Adjuvant tamoxifen has become the treatment of choice against estrogen receptor-positive breast cancer. Adverse effects are rarely observed and since symptoms of hepatic steatosis, non-alcoholic steatohepatitis and cirrhosis are usually negligible, such effects are not well characterized despite large cohort studies of adjuvant tamoxifen. This issue remains to be systematically studied. The present study consisted of 136 breast cancer patients treated with or without tamoxifen. Patients had laboratory tests once each month and underwent abdominal computed tomography (CT) annually for 5 years. The extent of hepatic steatosis was assessed by CT as the liver/spleen ratio. While receiving adjuvant tamoxifen, 40 of 105 patients developed hepatic steatosis (liver/spleen ratio <0.9) without obvious changes in body mass index. Twenty-one had a liver spleen ratio of <0.5, whereas none of the 31 patients treated without tamoxifen had a ratio <0.9 or <0.5 (p<0.0001 and p<0.0001, respectively). Hepatic steatosis was recognized in 35 of the 40 patients within the first 2 years of receiving adjuvant tamoxifen and 21 of the 40 had increased transaminase levels. Liver biopsy revealed NASH in 6 of 7 patients among the 21 with a liver/spleen ratio of <0.5. A subset of individuals given adjuvant tamoxifen developed progressive hepatic steatosis without significant changes in the body mass index. We suggest a liver/spleen ratio of <0.5 as a criterion upon which liver biopsy should be recommended since NASH frequently occurred in such patients.
Similar articles
- Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Hamada N, Ogawa Y, Saibara T, Murata Y, Kariya S, Nishioka A, Terashima M, Inomata T, Yoshida S. Hamada N, et al. Int J Oncol. 2000 Dec;17(6):1119-23. doi: 10.3892/ijo.17.6.1119. Int J Oncol. 2000. PMID: 11078796 - Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis.
Murata Y, Ogawa Y, Saibara T, Nishioka A, Takeuchi N, Kariya S, Onishi S, Yoshida S. Murata Y, et al. Oncol Rep. 2003 Jan-Feb;10(1):97-100. Oncol Rep. 2003. PMID: 12469151 - Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?
Osman KA, Osman MM, Ahmed MH. Osman KA, et al. Expert Opin Drug Saf. 2007 Jan;6(1):1-4. doi: 10.1517/14740338.6.1.1. Expert Opin Drug Saf. 2007. PMID: 17181445 Review. - [Drug-induced Nonalcoholic Steatohepatitis].
Miyamura M, Yokota J, Saibara T. Miyamura M, et al. Yakugaku Zasshi. 2016;136(4):579-82. doi: 10.1248/yakushi.15-00264-3. Yakugaku Zasshi. 2016. PMID: 27040342 Review. Japanese.
Cited by
- The effect and mechanism of tamoxifen-induced hepatocyte steatosis in vitro.
Zhao F, Xie P, Jiang J, Zhang L, An W, Zhan Y. Zhao F, et al. Int J Mol Sci. 2014 Mar 5;15(3):4019-30. doi: 10.3390/ijms15034019. Int J Mol Sci. 2014. PMID: 24603540 Free PMC article. - Impact of steatosis on perioperative outcome following hepatic resection.
Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, DeMatteo RP, D'Angelica M, Blumgart LH, Jarnagin WR. Kooby DA, et al. J Gastrointest Surg. 2003 Dec;7(8):1034-44. doi: 10.1016/j.gassur.2003.09.012. J Gastrointest Surg. 2003. PMID: 14675713 - Association of Platelet-Monocyte Ratio with Dyslipidemia in Saudi Arabia: A Large, Population-Based Study.
Alfhili MA, Alotaibi GA, Alfaifi M, Almoghrabi Y, Alsughayyir J. Alfhili MA, et al. Life (Basel). 2023 Aug 4;13(8):1685. doi: 10.3390/life13081685. Life (Basel). 2023. PMID: 37629542 Free PMC article. - Influence of gender on tamoxifen-induced biochemical changes in serum of rats.
Hemieda FA. Hemieda FA. Mol Cell Biochem. 2007 Jul;301(1-2):137-42. doi: 10.1007/s11010-006-9405-2. Epub 2007 Feb 6. Mol Cell Biochem. 2007. PMID: 17279326 - Integrating Drug's Mode of Action into Quantitative Structure-Activity Relationships for Improved Prediction of Drug-Induced Liver Injury.
Wu L, Liu Z, Auerbach S, Huang R, Chen M, McEuen K, Xu J, Fang H, Tong W. Wu L, et al. J Chem Inf Model. 2017 Apr 24;57(4):1000-1006. doi: 10.1021/acs.jcim.6b00719. Epub 2017 Apr 10. J Chem Inf Model. 2017. PMID: 28350954 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical